KODIAK SCIENCES DL-0001(K27)

Description: Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

---

Keywords: Macular Degeneration Diabetic Retinopathy Blindness Wet Age Related Macular Degeneration Retinopathy Diabetic Macular Edema Macular Edema Retinal Diseases Vascular Endothelial Growth Factor Aflibercept Retinal Vein Occlusion Angiogenesis Inhibitors Central Retinal Vein Occlusion Non Proliferative Diabetic Retinopathy

---

Home Page: kodiak.com

1200 Page Mill Road
Palo Alto, CA 94304
United States
Phone: 650 281 0850

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)